Remote monitoring with Caaring for people with reduced ejection fraction heart failure
Official title: Determination of the Efficacy of Remote Monitoring of Patients With Heart Failure and Reduced Ejection Fraction Using Caaring® Software
Run by Persei Vivarium · NCT06920160 · Data updated 2026-11-12
Test whether using the Caaring smartphone app for remote monitoring helps people with reduced ejection fraction heart failure avoid hospital readmission over 12 weeks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 196 (estimated) |
| Sponsor | Persei Vivarium Academic / other |
| Locations | 2 sites (Ferrol, A Coruña and 1 other locations) |
| Status | Recruiting |
| Started | April 15, 2025 |
| Main results expected | July 2025 |
| Study ends | August 2025 |
| Registry record updated | June 4, 2025 |
| Trial ID | NCT06920160 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with heart failure and reduced ejection fraction (EF ≤40%) recently discharged after an acute heart failure episode or in follow-up who routinely use a smartphone and can give informed consent.
✕Probably not a fit
Patients who cannot use a smartphone, have cognitive or significant sensory impairments without a legal representative, or who cannot complete follow-up due to relocation are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, multicenter, non-inferiority trial compares remote telemonitoring via the Caaring® software to routine prospective follow-up in patients with heart failure and reduced ejection fraction. Participants are randomly assigned to the Caaring telemonitoring arm or a prospective control arm, with clinical data collected for 12 weeks after inclusion. The Caaring platform supports patient self-management and captures remote symptom and device-reported data through the patient’s smartphone to trigger clinical alerts. The primary comparison focuses on rates of rehospitalization or clinical re-entries during the follow-up period.
Why it matters
Potential benefit: If successful, the app could reduce hospital readmissions and improve self-management for people with reduced ejection fraction heart failure.
How similar studies have gone: Previous telemonitoring and remote-monitoring trials in heart failure have shown mixed but sometimes positive results on readmissions and self-care, while Caaring® itself appears novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Patients diagnosed with heart failure with reduced ejection fraction (EFS40%) * Patients discharged after an episode of acute heart failure and/or patients who are being followed up after being admitted for heart failure. * Patients who extensively use a smartphone. * lnformed Consent is obtained from the patient Exclusion Criteria: * Patients with cognitive ar sensory difficulties or with insufficient command of Spanish who, in the opinion of the investigator, makes it difficult to understand the questions ar the scales, as long as they do not have a legally authorized representative capable of participating in the study. * Transient patients in whom it may be anticipated that follow-up will not be completed due to a change of residence. * Patients Who are participating at the time of recruitment in any other clinical trial. Participation in observational studies will not be an exclusion criteria. * Patients whose main diagnosis is a poorly controlled mental disorders ar other medical illness. * Patients with terminal illness and/or in palliative care according to the criteria of the SECPAL (Spanish Society of Palliative Care). * lnstitutionalized patients * Patients who are pregnant ar breastfeeding. * Patients whose inclusion is not considered advisable by the investigator's assessment due to they are under specific follow-up in other hospital units (hemodialysis, transplants, etc.) that require mandatory hospital attendance less frequently than once every two months.
Where it's running
-
Hospital Universitario de Son Llatzer
Palma de Mallorca, Balearic Islands, Spain Recruiting -
Complejo Hospitalario Universitario de Ferrol
Ferrol, A Coruña, Spain Not yet recruiting
Study contacts
- Study coordinator: Roberto Bravo
- Email: roberto.bravo@perseivivarium.com
- Phone: +34 915004013
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Yoga-based cardiac rehabilitation for heart failure with reduced ejection fraction
This trial tests whether a yoga-based rehabilitation program can help people with heart failure and reduced ejection fraction compared with an educational program.
-
Lumacaftor to improve cerebral blood flow in heart failure with reduced ejection fraction
This study tests whether lumacaftor can improve brain blood flow and thinking abilities in adults with a certain type of heart failure.
-
Stepwise withdrawal of ARNI and SGLT2i in HF with normalized ejection fraction
This trial tests whether gradually stopping ARNI and SGLT2i is safe for people whose heart function has recovered after fixing a reversible heart‑disease cause.
-
Ring-style blood pressure bracelet test compared with 24-hour monitoring in people with HFrEF
A ring-type blood pressure device is being tested to see if its 24-hour readings match those from standard ambulatory monitoring in adults with heart failure and reduced ejection fraction.
-
Diet and exercise plan to help people with heart failure and preserved heart function.
This study tests whether a DASH-style, high-protein diet, resistance exercise, or both can help build muscle and improve fitness and quality of life in people with heart failure and reduced ejection fraction.
-
HFrEF polypill strategy in Sri Lanka
This study tests whether giving a heart failure polypill can reduce death from heart disease and hospitalizations in adults with HFrEF in Sri Lanka, compared with usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.